

**SANGAMO BIOSCIENCES AND MEDAREX ANNOUNCE COLLABORATION
TO DISCOVER AND DEVELOP THERAPEUTIC ANTIBODIES
TO G-PROTEIN COUPLED RECEPTORS**

Richmond, California and Princeton, New Jersey – June 11, 2001 – Sangamo BioSciences, Inc. (Nasdaq: SGMO) and Medarex, Inc. (Nasdaq: MEDX) announced today a strategic collaboration to develop fully human antibody therapeutics for certain G protein-coupled receptors (GPCRs), a class of cell surface receptors widely regarded as an important source of novel drug targets for a number of serious diseases. The two companies will work exclusively on fully human antibody products that are jointly developed by the collaboration and will share costs and commercialization rights to such products.

Cells routinely communicate with one another in order to carry out normal physiological functions. When this intercellular communication goes awry, a number of different disease states can occur. GPCRs, which transmit these signals across cell membranes, have been implicated in a number of diseases. In fact, many therapeutics used today act by influencing GPCR signaling pathways. Since a number of GPCRs have yet to be identified, a significant amount of drug discovery research is focused on increasing the understanding of these important proteins.

Under the terms of the agreement, Sangamo will use its proprietary zinc finger DNA-binding protein transcription factor (ZFP TF) technology to create cell lines that over express selected GPCRs. Medarex expects to use its UltiMAb™ Human Antibody Development SystemSM to generate fully human antibodies to these GPCRs.

Produced by the immune system, antibodies are proteins that recognize and bind to a particular site on cells, viruses, and other organisms. They are generated in response to foreign substances called antigens; in this case, human GPCRs. Antibody products are now on the market for a variety of indications, including cancer, heart disease, and transplant rejection. In addition, a large number of pharmaceutical and biotechnology companies are exploring antibody technology to develop new products.

“With their increasing validation as therapeutically important drug targets, GPCRs continue to be an area of intense and promising drug discovery research,” said Donald L. Drakeman, Medarex’s president and chief executive officer. “Sangamo’s ZFP TF technology provides a unique and proprietary approach to create fully human antibody products to any clinically relevant GPCR. We intend to examine a number of different GPCRs that may be implicated in a variety of diverse diseases.”

“Our technology, coupled with Medarex’s established expertise in fully human antibody products, represents a novel approach for discovering and developing new GPCR-based therapeutics,” said Edward Lanphier, Sangamo’s president and chief executive officer. “The opportunity to work with a company of Medarex’s stature to explore this promising drug discovery approach is extremely exciting. This agreement also represents another example of how Sangamo’s ZFP TF technology can be applied for therapeutic product development, underscoring the breadth of our technology platform.”

Sangamo BioSciences, Inc.
Point Richmond Tech Center
501 Canal Blvd., Suite A100
Richmond, CA 94804
510-970-6000 • 510-236-8951(Fax)

About Sangamo

Sangamo is focused on the research and development of novel transcription factors for the regulation of gene expression. Sangamo's Universal Gene Recognition™ technology enables the engineering of a particular class of transcription factors known as zinc finger DNA-binding proteins. By engineering zinc finger DNA-binding proteins so that they can recognize a specific gene, Sangamo has created zinc finger DNA-binding protein transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. The company intends to establish Universal Gene Recognition as a widely used technology for commercial applications in pharmaceutical discovery, human therapeutics, clinical diagnostics, agriculture and industrial biotechnology. Over twenty leading pharmaceutical and biotechnology companies have utilized ZFP TFs. In addition, Sangamo is developing novel ZFP TF-based therapeutics for the treatment of cardiovascular disease. For more information about Sangamo, visit the company's web site at www.sangamo.com.

About Medarex

Medarex is a biopharmaceutical company developing monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. Medarex has assembled a broad platform of patented technologies for antibody discovery and development, including the UltiMAB™ Human Antibody Development SystemSM for the creation of high-affinity, fully human antibodies; T-12 DevelopmentSM offering the potential to move from target to trial in approximately 12 months; and Trans-Phage TechnologySM combining high throughput screening with fully human antibody development. Medarex creates and develops fully human antibodies for itself and others, offering a full range of antibody development capabilities, including preclinical and clinical manufacturing services. For more information about Medarex, visit its web site at www.medarex.com.

This press release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the safe harbors created by those sections. Those forward-looking statements include statements related to the ability of Sangamo BioSciences, Inc. and Medarex, Inc. to discover, develop, and commercialize GPCR-based therapeutics and may include the words "believes"; "anticipates"; "intends"; "plans"; "expects"; "estimates"; or similar statements. Actual results may differ materially due to a number of factors, including numerous technological, operational and financial challenges associated with the regulation of genes and the development of novel human antibodies. The matters discussed in this press release also involve risks and uncertainties described in Sangamo's and Medarex's filings with the Securities and Exchange Commission (SEC). In particular, see the risk factors described in the companies' Annual Reports on Form 10-K and their most recent 10-Qs. Sangamo and Medarex assume no obligation to update the forward-looking information contained in this press release.

Contacts:

Julie Wood
Sangamo BioSciences, Inc.
510-970-6000, x256

Donald L. Drakeman
President and CEO
Medarex, Inc.
609-430-2880

Bea Evangelista
Middleberg Euro
for Medarex, Inc. (media)
212-699-2503
bea@middleberg.com

UltiMAB™ is a trademark of Medarex, Inc. Human Antibody Development SystemSM, T-12 DevelopmentSM and Trans-Phage TechnologySM are service marks of Medarex, Inc.

Universal Gene Recognition™ is a trademark of Sangamo BioSciences, Inc.

###